Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANO-ENGINE

Financiado

A revolutionary cell programming platform based on the targeted nano-delivery of...

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders.... ver más

31/03/2026

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 7 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-15

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

7 Participantes

725.24K€ | Lider

IMPERIAL COLLEGE OF SCIENCE...

N.D. | Participante

SINTEF

548.97K€ | Participante

NANOCELL THERAPEUTICS

1.14M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2017-91272-EXP ENTREGA DE COMPONENTES CRISPR FUNCIONALES MEDIANTE EL USO DE... 42K€ Cerrado

PCIN-2017-127 TERAPIA GENICA BASADA EN HIPERTERMIA MAGNETICA LOCALIZADA PA... 96K€ Cerrado

PCIN-2017-060 TERAPIA GENICA BASADA EN HIPERTERMIA MAGNETICA LOCALIZADA PA... 122K€ Cerrado

PID2021-124247OB-C22 TRANSPORTADORES DE ADN/ARN DE NUEVA GENERACION:CAPSIDES MOLE... 85K€ Cerrado

PID2020-114356RB-I00 VECTORES NO VIRALES PARA TERAPIA GENICA BASADOS EN NANOPARTI... 213K€ Cerrado

NANEMIAR Nanomedicine Approach to Normalize Erythrocyte Maturation in... 3M€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2023-03-15
Fecha Fin: 2026-03-31

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders. In this project, the consortium aims to assemble, characterize, and test the Targeted Nanoparticles, explore small-scale synthesis, conduct proof of concept studies and develop a preliminary business plan. Unmet need: Currently, the accessibility of cell therapies, specifically CAR-T cell therapy, to the general patient population is limited by high costs, complexity, and safety concerns. These limitations are caused by: 1) ex vivo manufacturing processes of adoptive cell technologies, 2) requirement of highly specialized clinical facilities, and 3) the clinical toxicities and the need for preconditioning chemotherapy. Therefore, there is a large unmet need for alternative approaches that makes adoptive cell therapy truly affordable, scalable, and widely accessible in an out-patient setting. Solution: We will develop Targeted Nanoparticles that form CAR-T cells in vivo, by combining a proprietary T cell binder-coated long-circulatory lipid nanoparticle and a non-viral, transposon-based, gene editing system. As such, we will circumvent the aforementioned issues associated with traditional cell therapies with reduced cost, complexity, and associated clinical risks, greatly increasing the accessibility of cell therapies to patients worldwide. Consortium: The consortium will leverage main applicant NANOCELL’s deep knowledge on non-viral gene transfer technologies. UU provides critical expertise on nanomedicine, protein and cell engineering. ICL has developed a revolutionary single particle analysis method, which allows the consortium to obtain unique drug product characterization insights. SINTEF adds crucial know-how on bulk analysis of Targeted Nanoparticles, and is closely involved in regulatory standards for nucleic acid therapeutics.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores